Office of the Clinical Director - The Intramural Research Program of the National Institute on Drug Abuse

Skip Navigation

Office of the Clinical Director


Office of the Clinical Director
BRC, Suite 200, Room 02A638
251 Bayview Blvd.,
Baltimore, MD 21224

Phone: 443.740.2360

Fax: 443.740.2859

The Archway Clinic - Click for larger version
The Archway Clinic - Click for larger version

Entrance to the Archway Clinic - Click for larger version
Entrance to the Archway Clinic - Click for larger version

The Archway Clinic's waiting area - click for larger version
The Archway Clinic's waiting area - click for larger version

A typical testing kit - click for larger version
A typical testing kit - click for larger version


Clinical Director: Karran Phillips, MD, MSC Email
Deputy Clinical Director: Robert Goodwin, DO, PhD. Email

The Office of the Clinical Director (OCD) coordinates, supports, and supervises the development, implementation and conduct of intramural clinical research activities. The OCD provides the infrastructure needed to promote top quality clinical research and to ensure research participant safety and confidentiality. This infrastructure includes a research participant recruitment and screening center, a 45-slot addiction treatment outpatient research clinic and multiple specialized study rooms (including smoking chambers, mock MRI scanner, and physiological monitoring). In addition, a digital medical record system on a secure network has been developed and allows for all research related data to be accessible from within the IRP.

The OCD provides clinical support personnel to complement research personnel in specific laboratory groups. The personnel include clinical research nurses, research associates, mid-level providers, research pharmacists, IRB administrators, and a quality assurance medical officer.

The clinical research portfolio at the NIDA IRP includes a wide variety of collaborative investigation that focus on:

  • Efficacy and safety of new treatments for drug abuse.
  • Factors that impact drug taking and relapse.
  • Application of MRI-based structural and functional imaging to elucidate acute and chronic drug effects and their consequences on cognitive processes.
  • Specific individual genetic polymorphisms and the group variance imaging endophenotypes to understand trait related predisposition and treatment outcome.
  • Molecular genetic bases of individual differences in vulnerability to develop dependence on an addictive substance.
  • Recruitment and characterization of subjects for genome wide association studies.
  • Development of advanced functional and structural magnetic resonance imaging/spectroscopy techniques.
  • Structural MRI techniques to assess tissue integrity related to brain dysfunction.
  • Transcranial magnetic Stimulation (TMS) in the elucidation and treatment of addictive disorders.
  • Mobile health applications for real-time in-the-field addiction treatment interventions.

The independent clinical investigators include:

Research Participant Recruitment and Screening

An integral component of Clinical Research for the NIDA IRP is participant recruiting and screening. Core services include advertising and media outreach to clinical research populations including healthy control participants, individuals with nicotine addiction, and individuals with opioid and other addictions, including those seeking and not seeking therapeutic intervention.

FAQ about Clinical Studies Participation

Administrative Management of the Clinical Research Program

The OCD is involved in:

  • the scientific, resource, and patient safety monitoring of all clinical research protocols,
  • overseeing protocol implementation and execution by assuring availability of support personnel, space, equipment, and supplies; assessing data safety and monitoring plans and quality assurance reviews of clinical records,
  • overseeing and training of clinical personnel and developing clinical policies and standard operating procedures in collaboration with the clinical investigators, the medically accountable investigators, and the clinical support staff,
  • hosting the NIDA IRP Clinical Rounds.

Institutional Review Board

All NIDA clinical research protocols are reviewed by the NIH Addictions Institutional Review Board.

Chair: Stephen J. Heishman, PhD

IRB Administrator: Michelle L. Jobes, PhD

Addictions IRB Office

Related Information...

Health and Human Services Logo National Institute on Drug Abuse Logo

The National Institute on Drug Abuse (NIDA), is part of the National Institutes of Health (NIH), the principal biomedical and behavioral research agency of the United States Government. NIH is a component of the U.S. Department of Health and Human Services.

PDF documents require the free Adobe Reader. Microsoft Word documents require the free Microsoft Word viewer. Microsoft PowerPoint documents require the free Microsoft PowerPoint viewer. Flash content requires the free Adobe Flash Player.